Huang Xueqin, Tian Hemi, Huang Lei, Chen Qiuxia, Yang Yingqi, Zeng Runmin, Xu Jun, Chen Shanze, Zhou Xia, Liu Guangqiang, Li Haoyu, Zhang Yuan, Zhang Jianglin, Zheng Junxia, Cai Huaihong, Zhou Haibo
The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen 518020, China.
College of Pharmacy, Jinan University, Guangzhou 510632, China.
Anal Chem. 2023 Apr 11;95(14):5955-5966. doi: 10.1021/acs.analchem.2c05640. Epub 2023 Mar 14.
Ultra-sensitive detection of cancer-related biomarkers in serum is of great significance for early diagnosis, treatment, prognosis, and staging of cancer. In this work, we proposed a surface-enhanced Raman scattering and fluorescence (SERS/FL) dual-mode biosensor for hepatocellular carcinoma (HCC)-related miRNA (miR-224) detection using the composition of well-arranged Au nanoarrays (Au NAs) substrate coupled with the target-catalyzed hairpin assembly (CHA) strategy. The hot spots densely and uniformly distributed on the Au array offers considerably enhanced and reproducible SERS signals, along with their wide and open surface to facilitate miR-224 adsorption. By this sensing strategy, the target miR-224 can be detected in a wide linear range (1 fM to 1 nM) with a limit of detection of 0.34 fM in the SERS mode and 0.39 fM in the FL mode. Meanwhile, this biosensor with exceptional specificity and anti-interference ability can discriminate target miR-224 from other interference miRNAs. Practical analysis of human blood samples also demonstrated considerable reliability and repeatability of our developed strategy. Furthermore, this biosensor can distinguish HCC cancer subjects from normal ones and monitor HCC patients before and after hepatectomy as well as guide the distinct Barcelona clinic liver cancer (BCLC) stages. Overall, benefiting from a well-arranged Au nanoarray, CHA amplification strategy, and SERS/metal enhanced fluorescence effect, this established biosensor opens new avenues for the early prediction, warning, monitoring, and staging of HCC.
超灵敏检测血清中癌症相关生物标志物对癌症的早期诊断、治疗、预后及分期具有重要意义。在本研究中,我们提出了一种表面增强拉曼散射和荧光(SERS/FL)双模式生物传感器,用于检测与肝细胞癌(HCC)相关的微小RNA(miR-224)。该传感器采用排列有序的金纳米阵列(Au NAs)基底结合目标催化发夹组装(CHA)策略。金阵列上密集且均匀分布的热点提供了显著增强且可重复的SERS信号,同时其宽阔开放的表面便于miR-224的吸附。通过这种传感策略,目标miR-224在宽线性范围(1 fM至1 nM)内均可被检测到,SERS模式下的检测限为0.34 fM,FL模式下的检测限为0.39 fM。同时,这种具有卓越特异性和抗干扰能力的生物传感器能够区分目标miR-224与其他干扰微小RNA。对人体血液样本的实际分析也证明了我们所开发策略具有相当高的可靠性和可重复性。此外,该生物传感器能够区分HCC癌症患者与正常受试者,监测HCC患者肝切除术前和术后的情况,并指导区分巴塞罗那临床肝癌(BCLC)分期。总体而言,得益于排列有序的金纳米阵列、CHA扩增策略以及SERS/金属增强荧光效应,这种新型生物传感器为HCC的早期预测、预警、监测及分期开辟了新途径。